📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-07 12:41
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
35 announcements match the current filters (relevance ≥ 5).
Granules Gains Potential Sole First-to-File Status for Ruxolitinib ER Tablets ANDA
Granules India Limited has submitted an ANDA with a Paragraph IV certification for Ruxolitinib Extended-Release Tablets. Based on the filing timeline, the company believes it is eligible for sole first-to-file status, which could grant 180 days of generic marketing exclusivity under U.S. law upon approval. The filing represents Granules' ongoing push into higher-value, technically complex generic formulations in the U.S. market. However, the application remains subject to FDA review, Paragraph IV litigation risks, and final determination of exclusivity status.
Confidence: HIGH
What changedGranules submitted a Paragraph IV ANDA for generic Ruxolitinib Extended-Release Tablets, positioning itself as a potential sole first-to-file applicant.
Why it mattersA confirmed first-to-file status with 180-day marketing exclusivity provides high-margin commercialization opportunities in the U.S., diversifying Granules away from standard commodity generics.
Exclusivity Period: 180 daysTotal Manufacturing Facilities: 10Market Presence: over 80 countries
📅 Short termWatch for the response from patent holders within the statutory 45-day window which may trigger standard Hatch-Waxman patent litigation.
📈 Long termIf successfully defended and approved with exclusivity, it supports Granules' strategy to expand into higher-margin, differentiated U.S. generic formulations.
⚠ Risk flags
- Potential patent litigation from the innovator leading to a 30-month stay of approval
- Exclusivity and ANDA remain pending final US FDA review and confirmation
Key Highlights
Submitted Paragraph IV certification for Ruxolitinib Extended-Release Tablets ANDA
Potential eligibility for 180 days of generic drug exclusivity under U.S. law upon approval
Serves as part of company's portfolio expansion across its 10 manufacturing facilities globally
Follows Granules' base of 91 total US FDA approvals as of recent filings
👀 What to Watch
Track whether the innovator initiates patent litigation within 45 days of notice, along with future FDA approval timelines and exclusivity confirmation.
Granules India Allots 2.50 Cr Equity Shares on Warrant Conversion; Raises ₹1,461.50 Cr
Granules India Limited has allotted 2,49,82,906 equity shares of face value Re. 1/- each to promoter group members upon conversion of warrants. The conversion was executed at an issue price of ₹585 per share, representing total proceeds of ₹1,461.50 crore (including the initial 25% upfront subscription). This equity infusion is substantial, equivalent to ~28.4% of TTM revenue (₹5,140 Cr) and ~7.1% of the company's current market cap. The total paid-up equity share capital expands from 24,77,96,921 to 27,27,79,827 shares, leaving 17,094 non-promoter warrants outstanding.
Confidence: HIGH
What changedGranules India converted 2.50 crore warrants into fully paid-up equity shares for promoter group entities after receiving the balance 75% subscription money.
Why it mattersThe company has received ₹1,461.50 crore in total capital, which significantly strengthens its net worth, de-leverages the balance sheet, and provides dry powder for ongoing growth initiatives (such as Senn Chemicals and Ascelis).
Shares allotted: 2,49,82,906Issue / Exercise price: Rs. 585/- per shareTotal consideration: Rs. 1,461.50 CroresFundraise vs TTM Revenue: ~28.4%Fundraise vs Market Cap: ~7.1%Post-issue share count: 27,27,79,827
📅 Short termSignals strong promoter commitment via cash infusion at ₹585/share, though the addition of ~2.50 crore shares (~10% equity expansion) causes slight EPS dilution.
📈 Long termSubstantially fortifies the balance sheet and liquidity profile to fund CDMO capex and peptide portfolio scaling, lowering leverage risks.
⚠ Risk flags
- Equity dilution of ~10% impacting future earnings per share (EPS)
- Execution risk on deploying large cash reserves profitably into planned CDMO and peptide assets
Key Highlights
Allotment of 2,49,82,906 equity shares at an issue price of ₹585 per share upon warrant conversion
Total consideration received stands at ₹1,461.50 crore (receipt of remaining 75% balance)
Paid-up share capital increases from ₹24,77,96,921 to ₹27,27,79,827
Promoter group member Ms. Chigurupati Uma Devi allotted 2,48,80,342 shares, raising her stake from 3.73% to 12.51%
Only 17,094 non-promoter warrants remain outstanding for conversion
👀 What to Watch
Track the upcoming quarterly shareholding patterns to verify updated promoter equity totals, and monitor management commentary regarding the deployment of proceeds toward CDMO/peptide expansions or debt reduction.
Granules India Receives ₹1,093 Cr from Promoters for Warrant Conversion; Turns Net Cash Surplus
Granules India announced that its promoter group has remitted the balance 75% subscription amount of ₹1,093 crore towards preferential convertible warrants. Consequently, 2,49,14,530 warrants are fully paid and eligible for conversion into equity shares. The capital infusion turns the company into a net cash surplus position on a consolidated basis, significantly exceeding its existing total debt of ₹828 crore. The proceeds will provide growth capital to accelerate business initiatives and capital expenditure ahead of schedule.
Confidence: HIGH
What changedPromoters completed the payment of ₹1,093 crore to convert 2.49 crore warrants into equity, wiping out net debt.
Why it mattersThe infusion strengthens the balance sheet to a net cash position and provides substantial dry powder to fund strategic growth and acquisitions without external debt.
Balance subscription received: Rs. 1,093 croresWarrants eligible for conversion: 2,49,14,530Balance payment percentage: 75%Inflow vs Net Worth: ~24.8%Inflow vs Total Debt: ~132%
📅 Short termStrengthens sentiment as promoters inject substantial equity cash, de-leveraging the balance sheet to a net cash status.
📈 Long termAccelerates long-term CAPEX and strategic M&A investments (e.g., Senn Chemicals, peptides) while improving return ratios and financial resilience.
⚠ Risk flags
- Equity dilution from the issuance of ~2.49 crore fresh equity shares upon conversion
Key Highlights
Promoter group paid balance 75% warrant subscription amount of ₹1,093 crore
2,49,14,530 warrants are now fully paid and eligible for conversion into equity shares
Inflow moves the company into a net cash surplus position on a consolidated basis
Capital inflow of ₹1,093 crore represents ~5.1% of market cap (₹21,468 Cr) and ~24.8% of net worth (₹4,399 Cr)
👀 What to Watch
Track the formal board allotment and listing of the 2,49,14,530 equity shares, along with updates on capital deployment towards CDMO and peptide expansion.
Promoter Sells 1.72 Cr Shares in Granules India; Group Stake Drops to 31.08%
Promoter Dr. Krishna Prasad Chigurupati sold 1,72,00,000 equity shares of Granules India on September 11, 2026, through block deals and the open market. Following the stake sale, aggregate Promoter and Promoter Group holding reduced from 38.02% to 31.08% (37.39% on a diluted basis). Dr. Chigurupati's individual holding fell from 31.00% to 24.06%. The proceeds will be used to fund the second tranche of the company's ongoing preferential issue and finance strategic growth initiatives.
Confidence: HIGH
What changedPromoter Dr. Krishna Prasad Chigurupati offloaded 1.72 crore shares, cutting overall promoter stake to 31.08% from 38.02%.
Why it mattersWhile promoter selling typically causes overhang, the proceeds are earmarked to fund a preferential issue back into the company to support faster-than-expected expansion.
Shares Sold: 1,72,00,000 equity sharesPromoter Group Pre-deal Stake: 38.02%Promoter Group Post-deal Stake: 31.08%Promoter Group Diluted Post-deal Stake: 37.39%Dr. Chigurupati Post-deal Stake: 24.06%
📅 Short termLarge secondary market supply is absorbed by institutional buyers, limiting extreme downward price pressure, though supply absorption will be monitored over coming sessions.
📈 Long termOn a diluted basis, promoter ownership will rebound towards 37.39% as preferential issue warrants/shares are subscribed, providing growth capital for CDMO and generic expansion.
⚠ Risk flags
- Reduction in undiluted promoter ownership down to 31.08%
- Execution risk on growth projects requiring early capital deployment
Key Highlights
Promoter Dr. Krishna Prasad Chigurupati sold 1,72,00,000 equity shares via block deal & open market on September 11, 2026
Aggregate Promoter and Promoter Group stake decreased from 38.02% to 31.08% (37.39% on a diluted basis)
Individual promoter holding reduced by 6.94% from 31.00% to 24.06%
Institutional buyers included Capital Group, ChrysCapital, Kotak Mahindra Life Insurance, and Allspring
Sale was executed to fund the second tranche of the company's ongoing preferential issue
👀 What to Watch
Track the infusion of funds from the preferential issue's second tranche into company balance sheets and watch for execution timelines of announced growth initiatives.
Granules India Appoints Sanjay Kumar as CEO of Ascelis Peptides Effective Aug 13, 2026
Granules India has internally transferred its Chief Strategy Officer, Mr. Sanjay Kumar, to the role of CEO at its wholly-owned subsidiary, Ascelis Peptides Private Limited, effective August 13, 2026. This move provides dedicated leadership to the company's peptide and specialized segments, which are central to its 15-20% growth target. Ascelis Peptides is a critical but currently loss-making unit, having reported an EBITDA loss of INR 20 Cr. The transition follows Granules' significant investments in the space, including the INR 450 Cr acquisition of Senn Chemicals AG.
Confidence: HIGH
What changedThe Chief Strategy Officer of the parent company has been moved to lead a key growth subsidiary as its CEO.
Why it mattersIt signals a shift from group-level strategy to execution-focused leadership for the specialized peptide business, which is vital for margin expansion beyond base generics.
Ascelis EBITDA Loss: INR 20 CrSenn Chemicals Acquisition: INR 450 CrParent TTM Revenue: Rs 4474 CrEffective Date: August 13, 2026
📅 Short termThe market is likely to view this as a routine internal realignment with no immediate impact on the stock price.
📈 Long termIf successful, dedicated leadership at Ascelis could accelerate the company's transition into high-value CDMO and peptide markets, improving overall group ROCE.
⚠ Risk flags
- Execution risk in turning around a loss-making subsidiary
- Dependency on the success of the peptide portfolio for future margin growth
Key Highlights
Mr. Sanjay Kumar transitions from Group Chief Strategy Officer to CEO of Ascelis Peptides on August 13, 2026
Ascelis Peptides is a 100% wholly-owned subsidiary focused on the high-margin peptide portfolio
The parent company maintains a TTM revenue of Rs 4,474 Cr with a 21.6% operating margin
Management aims to address the INR 20 Cr EBITDA loss previously reported by the Ascelis unit
The move supports the integration of the INR 450 Cr Senn Chemicals acquisition into the CDMO vertical
👀 What to Watch
Monitor the next two quarterly results for Ascelis Peptides to see if dedicated leadership leads to a reduction in EBITDA losses and faster product filings.
60% PAT Growth in Q1 FY27; Complex Generics Reach 50% of Finished Dosages
Granules India reported its strongest Q1 ever, with revenue growing 22% YoY to ₹1,477 cr and PAT surging 60% to ₹180 cr. The company is successfully shifting its product mix, with complex generics now accounting for 50% of finished dosages, up from 39% a year ago. Financial health is robust with ROCE improving to 18% and the company becoming virtually debt-free with a Net Debt/EBITDA of 0.07x. Management confirmed that remediation at the Gagillapur facility is complete, with 9 product applications currently awaiting regulatory clearance to launch.
Confidence: HIGH
What changedThe company has successfully transitioned half of its finished dosage portfolio to complex generics and significantly deleveraged its balance sheet to near-zero net debt.
Why it mattersThe shift toward complex generics and Peptides (CDMO) improves margins and ROCE (now 18%), reducing the company's historical dependence on high-volume, low-margin commodity generics.
Q1 Revenue vs TTM Revenue: 33%PAT Growth (YoY): 60%Complex Generics Share: 50%Net Debt/EBITDA: 0.07xFormulation Capacity Addition: 40%ROCE: 18%
📅 Short termThe stock is likely to react positively to the significant earnings beat and the improvement in cash flow and debt metrics.
📈 Long termStructural shift toward innovation-led CDMO and complex generics provides a path for sustainable 15-20% growth and potential valuation re-rating.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory delay in Gagillapur clearance
- Litigation risks for first-to-file products
- Product concentration in top 5 molecules
Key Highlights
Revenue grew 22% YoY to ₹1,477 cr, representing approximately 33% of the previous TTM revenue in a single quarter.
PAT increased 60% YoY to ₹180 cr, supported by healthy gross margins of 65.6%.
Complex generics share of finished dosages rose to 50%, compared to 39% in the same quarter last year.
Peptide CDMO business (Senn Chemicals) delivered over 100% YoY growth, contributing CHF 5 million in Q1.
Generated ₹387 cr in operating cash flow during the quarter, reducing Net Debt/EBITDA to 0.07x.
👀 What to Watch
Monitor the US FDA's final clearance for the Gagillapur facility, which will unlock 9 pending product launches. Additionally, track the utilization ramp-up at the new Genome Valley facility, which adds 40% to total formulation capacity.
60% YoY PAT Growth to INR 1,800 Mn; Net Debt Reduced by INR 8,467 Mn in Q1 FY27
Granules India reported a robust Q1 FY27 with revenue increasing 22% YoY to INR 14,768 Mn, representing approximately 33% of TTM revenue. Net profit (PAT) surged 60% YoY to INR 1,800 Mn, supported by an improved EBITDA margin of 23% compared to 20% in the year-ago period. A significant highlight is the aggressive deleveraging, with net debt decreasing by INR 8,467 Mn YoY to just INR 1,012 Mn, resulting in a low Net Debt to EBITDA ratio of 0.07x. While North America remains the dominant market at 72% of revenue, the company is seeing growth in Europe and its new Peptides CDMO segment which now contributes 4% of revenue.
Confidence: HIGH
What changedGranules reported its Q1 FY27 results showing strong double-digit growth in revenue and profits alongside a massive reduction in debt.
Why it mattersThe significant jump in PAT and ROCE indicates improved operational efficiency and a successful shift toward higher-margin finished dosages and complex products, while the debt reduction strengthens the balance sheet for future expansions.
Revenue from Operations: INR 14,768 MnPAT: INR 1,800 MnNet Debt Reduction (YoY): INR 8,467 MnROCE: 18.0%Revenue vs TTM Revenue: ~33%Net Debt to EBITDA: 0.07x
📅 Short termThe stock is likely to react positively to the strong YoY profit growth and the significant improvement in the debt profile.
📈 Long termStructural improvements in ROCE and the growing contribution from the Peptides CDMO segment suggest a successful transition toward a more complex and margin-accretive product portfolio.
⚠ Risk flags
- High geographic concentration with 72% revenue from North America
- Management warning on supply chain volatility for the next two quarters
- Product concentration in top 5 molecules
Key Highlights
PAT grew 60% YoY to INR 1,800 Mn in Q1 FY27 compared to INR 1,126 Mn in Q1 FY26
Net debt saw a sharp reduction of INR 8,467 Mn from Q1 FY26 levels, standing at INR 1,012 Mn
Finished Dosages (FD) remains the core driver, contributing 74% of total revenue in Q1 FY27
ROCE improved to 18.0% in Q1 FY27 from 17.6% in the full year FY26
EBITDA margins expanded to 23% in Q1 FY27 from 20% in Q1 FY26, despite a 4% QoQ dip
👀 What to Watch
Watch the scaling of the Peptides CDMO business and the management's ability to navigate 'external cost pressures and supply chain volatility' mentioned for the next two quarters.
Granules Secures Sole First-to-File (FTF) Status for Sodium Oxybate ER Oral Suspension
Granules India has achieved Sole First-to-File (FTF) status for its Abbreviated New Drug Application (ANDA) for Sodium Oxybate Extended-Release for Oral Suspension, the generic version of LUMRYZ®. This marks the company's second Sole FTF achievement, following its success with Amphetamine ER Tablets. Sole FTF status typically grants 180 days of market exclusivity in the U.S., which can lead to significantly higher margins and market share during the exclusivity period. This development aligns with Granules' strategy to transition from high-volume base generics to high-value complex generics.
Confidence: HIGH
What changedGranules has transitioned from a standard generic filer to a Sole First-to-File status holder for a complex, differentiated product in the U.S. market.
Why it mattersSole FTF status provides a temporary monopoly in the generic market, which is highly margin-accretive and helps diversify the company's revenue away from its top 5 commodity-like products.
Sole FTF ANDAs to date: 2Total Manufacturing Facilities: 11TTM Revenue: ₹ 4474 CrTTM Operating Profit Margin: 21.6%
📅 Short termThe announcement is likely to be viewed positively by the market as it validates the company's R&D pipeline and potential for high-margin U.S. sales.
📈 Long termThis reinforces Granules' structural shift toward complex generics and controlled substances, which is critical for long-term margin expansion and reducing pricing pressure from base generics.
⚠ Risk flags
- Potential patent litigation from the innovator (Alkermes)
- Regulatory compliance risks at manufacturing sites
- Execution risk in commercializing complex oral suspensions
Key Highlights
Secured Sole First-to-File (FTF) status for Sodium Oxybate Extended-Release for Oral Suspension.
Product is the generic equivalent of LUMRYZ®, used for treating cataplexy or excessive daytime sleepiness in narcolepsy patients.
This is the 2nd Sole FTF ANDA for the company, demonstrating increased R&D capability in complex generics.
Granules currently operates 11 manufacturing facilities across India, USA, and Switzerland to support its global portfolio.
👀 What to Watch
Investors should monitor the U.S. FDA's final approval timeline and the subsequent commercial launch date to gauge the timing of the 180-day exclusivity period's impact on earnings.
Granules India Receives USFDA EIR with VAI Status for Chantilly Facility
Granules India's US-based subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received an Establishment Inspection Report (EIR) from the USFDA for its facility in Chantilly, Virginia. The inspection, which took place from March 30 to April 3, 2026, resulted in a Voluntary Action Indicated (VAI) classification. Although four Form 483 observations were issued during the audit, the VAI status indicates that the facility is considered to be in a state of compliance. This clearance is vital for the company's continued manufacturing and supply operations within the United States.
Key Highlights
Received USFDA EIR for the Chantilly, Virginia facility with a VAI classification.
The inspection was conducted between March 30 and April 3, 2026.
Four Form 483 observations were issued during the inspection process.
The Chantilly facility is a wholly-owned subsidiary and a key component of Granules' global supply network.
👀 What to Watch
Investors should view this as a positive development as it resolves regulatory uncertainty regarding a key US manufacturing site. No immediate action is required, but this strengthens the company's compliance track record in regulated markets.
Granules India FY26 Revenue Hits ₹53,656 Mn; Gross Margin Rises to 65% on Complex Generic Shift
Granules India reported a strong FY26 with revenue growing 20% YoY to ₹53,656 million, crossing a major milestone. The company achieved record gross margins of 65%, up 355 basis points, driven by a strategic shift toward high-value complex generics. The newly acquired Senn Chemicals (Peptide CDMO) contributed ₹1,593 million in revenue and turned EBITDA positive in Q4. Despite ongoing regulatory remediation at the Gagillapur site, the company has maintained six consecutive quarters of sequential growth.
Key Highlights
FY26 revenue reached ₹53,656 million, a 20% YoY increase, driven by strong performance in North America and Europe.
Gross margins expanded to 65% due to improved product mix and the scaling of the Virginia (GPI) facility.
The US subsidiary (GPI) jumped to the 27th position among US generic companies by sales value, up from 74th in FY21.
Peptide CDMO vertical generated ₹1,593 million in FY26 revenue and achieved positive EBITDA in the final quarter.
Europe revenue grew 81% YoY, now contributing 15% of the total revenue base.
👀 What to Watch
Investors should focus on the upcoming US FDA re-inspection of the Gagillapur facility, as 9 pending product approvals are tied to its clearance. The successful turnaround of the peptide business and margin expansion provide a strong foundation for FY27 growth.
Granules India FY26 Net Profit Jumps 25.5% to ₹4,007 Million; Revenue Up 14.6%
Granules India reported a strong performance for the financial year ended March 31, 2026, with annual revenue growing 14.6% YoY to ₹34,739.60 million. The company's net profit for the full year saw a significant increase of 25.5%, reaching ₹4,006.67 million compared to ₹3,193.36 million in the previous fiscal. For the fourth quarter, revenue grew 14.1% YoY to ₹8,768.21 million. The company also demonstrated improved financial health by reducing its current borrowings from ₹8,081.93 million to ₹7,336.80 million.
Key Highlights
Annual Net Profit grew by 25.5% YoY to ₹4,006.67 million in FY26.
Total Revenue from operations for FY26 increased to ₹34,739.60 million from ₹30,301.63 million.
Q4 FY26 Revenue rose 14.1% YoY to ₹8,768.21 million compared to ₹7,680.26 million in Q4 FY25.
Full-year Earnings Per Share (EPS) improved to ₹16.48 from ₹13.17 in the previous year.
Current borrowings were reduced by ₹745.13 million during the fiscal year.
👀 What to Watch
The strong double-digit growth in both revenue and profitability, coupled with debt reduction, reflects high operational efficiency. Investors may consider this a positive signal for long-term value, though they should monitor the sustainability of margins in the competitive pharma sector.
Granules Q4FY26 PAT Jumps 33% YoY to INR 2,016 Mn; EBITDA Margins Expand to 24%
Granules India reported a strong Q4FY26 with revenue growing 23% YoY to INR 14,706 Mn and PAT increasing 33% YoY to INR 2,016 Mn. EBITDA margins saw a significant expansion to 24% from 21% in the previous year, driven by a better product mix and operational efficiencies. The company successfully reduced its net debt by INR 3,040 Mn over the year, bringing the Net Debt to EBITDA ratio down to a healthy 0.34x. Notably, the revenue share from Europe doubled to 17%, while the new Peptide/CDMO segment contributed 5% to the quarterly revenue.
Key Highlights
Q4FY26 Revenue grew 23% YoY to INR 14,706 Mn, while PAT rose 33% YoY to INR 2,016 Mn.
EBITDA margins expanded by 300 bps YoY to 24%, with EBITDA reaching INR 3,521 Mn (+40% YoY).
Net debt significantly reduced by INR 3,040 Mn YoY to INR 4,021 Mn; Net Debt/EBITDA stands at 0.34x.
Geographic diversification improved as Europe's revenue share rose to 17% from 8% YoY.
Full-year FY26 ROCE improved to 17.6% compared to 16.6% in the previous fiscal year.
👀 What to Watch
Investors should view these results positively due to the strong margin expansion and significant deleveraging of the balance sheet. The growth in the high-margin Peptide/CDMO segment and increased European market penetration provide a promising outlook for future earnings quality.
Granules India FY26 Revenue Hits ₹53,656 Mn, Up 20%; PAT Grows 19% to ₹5,950 Mn
Granules India achieved a significant milestone in FY26, surpassing ₹50,000 Mn in revenue with 20% YoY growth. The company witnessed structural margin expansion, with gross margins reaching 65% driven by a strategic shift toward Complex Generics, which now account for 43% of formulation sales. Financial health improved significantly as Net Debt to EBITDA dropped to 0.34x from 0.75x. The newly launched CDMO vertical and an 81% surge in European revenue emerged as key growth catalysts.
Key Highlights
FY26 Revenue grew 20% YoY to ₹53,656 Mn, surpassing the ₹50,000 Mn milestone for the first time.
Gross Margin expanded by 355 bps to 65.0%, while EBITDA grew 25% YoY to ₹11,851 Mn.
Complex Generics share in the Formulations segment increased to 43% from 31% in FY25.
Net Debt to EBITDA improved to 0.34x, supported by an equity infusion of ₹6,656 Mn.
Europe revenue grew by 81% YoY, and the new CDMO platform contributed ₹1,593 Mn in its first year.
👀 What to Watch
Investors should note the successful transition from volume-led to value-led growth through complex generics and CDMO services. The significant deleveraging and margin expansion provide a strong foundation for long-term capital appreciation.
Granules India FY26 PAT Jumps 25% to ₹4,007 Mn; Recommends ₹1.75 Final Dividend
Granules India reported a strong performance for the financial year ended March 31, 2026, with standalone revenue growing 14.6% YoY to ₹34,739.6 million. Net profit for the full year rose significantly by 25.5% to ₹4,006.67 million compared to ₹3,193.36 million in the previous year. The Board has recommended a final dividend of ₹1.75 per share, representing 175% of the face value. The company's balance sheet remains robust with total assets increasing to ₹59,812.79 million as of March 31, 2026.
Key Highlights
Full-year FY26 Revenue from operations increased to ₹34,739.60 million from ₹30,301.63 million in FY25.
Net Profit for FY26 grew by 25.5% YoY to ₹4,006.67 million.
Board recommended a final dividend of ₹1.75 per share (175%) for the financial year 2025-26.
Earnings Per Share (EPS) improved to ₹16.48 for the full year from ₹13.17 in the previous year.
Standalone Q4 FY26 revenue stood at ₹8,768.21 million, up from ₹7,680.26 million in the same quarter last year.
👀 What to Watch
Investors should view the strong double-digit growth in both revenue and profitability as a positive sign of operational scaling. The consistent dividend payout and improved EPS make it a healthy pick for long-term pharmaceutical sector exposure.
Granules India FY26 Net Profit Rises 25.5% to ₹4,007 Million; Revenue Up 14.6%
Granules India reported a robust performance for the full year ended March 31, 2026, with standalone revenue growing 14.6% YoY to ₹34,739.60 million. Net profit for the year surged by 25.5% to ₹4,006.67 million, reflecting improved operational efficiency and sales growth. For the fourth quarter, revenue stood at ₹8,768.21 million with a profit of ₹989.87 million. Additionally, the company successfully reduced its current borrowings to ₹7,336.80 million, indicating better cash flow management and a stronger balance sheet.
Key Highlights
Standalone Revenue for FY26 reached ₹34,739.60 million, a 14.6% increase over FY25's ₹30,301.63 million.
Net Profit for the full year grew to ₹4,006.67 million from ₹3,193.36 million in the previous year.
Annual Earnings Per Share (EPS) rose significantly to ₹16.48 from ₹13.17 YoY.
Current financial borrowings were reduced from ₹8,081.93 million to ₹7,336.80 million during the fiscal year.
Total Equity increased to ₹43,991.16 million as of March 31, 2026, compared to ₹34,030.10 million in the previous year.
👀 What to Watch
The strong double-digit growth in both top-line and bottom-line, coupled with effective debt reduction, reinforces the company's growth trajectory. Investors should view these results as a positive indicator of long-term value creation and operational stability.
Granules India Subsidiary Receives VAI Classification from US FDA for Shamirpet Facility
Granules India's wholly owned subsidiary, Granules Life Sciences, has received a Voluntary Action Indicated (VAI) classification from the US FDA for its Shamirpet facility in Telangana. The Establishment Inspection Report (EIR) follows a cGMP and pre-approval inspection conducted between December 15 and 19, 2025. The US FDA has officially closed the inspection with no regulatory actions recommended, providing a clear path for oral solid dosage manufacturing. This outcome enables multi-site manufacturing for approved products, enhancing the company's operational flexibility and supply chain reliability for the US market.
Key Highlights
US FDA issued an Establishment Inspection Report (EIR) with VAI classification for the Shamirpet manufacturing unit.
The inspection was conducted from December 15 to 19, 2025, covering oral solid dosage manufacturing operations.
The regulatory body has officially closed the inspection and recommended no further regulatory actions.
The clearance enables multi-site manufacturing capabilities for approved products across Granules' facility network.
Granules India maintains a global footprint with 11 manufacturing facilities, including 8 in India and 2 in the USA.
👀 What to Watch
This is a positive regulatory development that de-risks the company's manufacturing operations and supports future product launches. Investors should maintain confidence in Granules' compliance track record and its ability to service the regulated US market.
Granules India's US Packaging Facility Receives US FDA EIR with NAI Status
Granules India's US subsidiary, Granules Consumer Health, LLC, has received an Establishment Inspection Report (EIR) with 'No Action Indicated' (NAI) status from the US FDA. The inspection was conducted at its Manassas, Virginia packaging facility between December 1 and 3, 2025. This marks the second consecutive time the facility has cleared an FDA audit with zero observations, following a similar result in March 2023. The facility serves as a critical distribution hub for the company's US front-end OTC and prescription product operations.
Key Highlights
Received US FDA EIR with No Action Indicated (NAI) status for the Virginia packaging facility.
The inspection was conducted from December 1 to 3, 2025, resulting in zero observations.
Second consecutive successful FDA audit for this facility following the March 2023 inspection.
The site operates three advanced packaging lines for OTC and prescription (Rx) products.
Facility handles controlled substances and serves as a primary US distribution hub.
👀 What to Watch
This regulatory clearance confirms Granules' strong compliance culture and ensures no supply chain disruptions for its US OTC business. Investors should maintain a positive outlook on the stock given its consistent track record of zero-observation audits.
Granules India Allots Equity and Warrants Worth Rs 1,762.5 Cr at Rs 585/Share
Granules India has successfully allotted 51.28 lakh equity shares to institutional investors and 2.5 crore convertible warrants to the promoter group and select non-promoters. The allotment was priced at Rs 585 per share/warrant, with the company immediately raising Rs 300 crore from equity and Rs 365.6 crore as a 25% upfront warrant payment. This significant capital infusion, largely backed by the promoter group, indicates strong internal confidence and provides a substantial war chest for future growth. On a fully diluted basis, the total share capital will increase to 27.28 crore shares.
Key Highlights
Allotted 51,28,205 equity shares at Rs 585 each, raising Rs 300 crore from 360 ONE institutional funds.
Issued 2,50,00,000 convertible warrants at Rs 585 each, with 25% (Rs 365.62 crore) received upfront.
Promoter group subscribed to the majority of warrants, with Mrs. Chigurupati Uma Devi taking 2.48 crore warrants.
Total potential capital to be raised via warrants is Rs 1,462.5 crore within an 18-month conversion window.
Paid-up equity capital increased to Rs 24.78 crore and will reach Rs 27.28 crore on a fully diluted basis.
👀 What to Watch
Investors should view the promoter participation at Rs 585 as a strong signal of confidence in the company's valuation and future prospects. Monitor upcoming quarterly results for commentary on how this capital will be deployed for expansion or debt management.
Granules India to Issue 2.5 Cr Warrants and 51.28 Lakh Equity Shares via Preferential Issue
Granules India has received shareholder approval for a significant fundraise through a preferential issue of securities. The company plans to issue up to 2,50,00,000 convertible warrants and 51,28,205 equity shares to specific investors. The pricing will be subject to recomputation as per SEBI ICDR Regulations if required. Until the proceeds are fully utilized for their intended objects, the funds will be parked in low-risk instruments like debt mutual funds and government securities.
Key Highlights
Authorized issuance of up to 2,50,00,000 warrants convertible into equity shares
Authorized issuance of up to 51,28,205 equity shares on a preferential basis
Shareholder approval for the resolutions was obtained in the EGM held on January 22, 2026
Pricing of securities to be recomputed in compliance with SEBI ICDR Regulations where necessary
Unutilized proceeds to be temporarily invested in debt mutual funds, bank deposits, or government securities
👀 What to Watch
Investors should track the final allotment price and the specific end-use of funds to assess the long-term growth potential versus equity dilution. The move indicates a strong intent to raise capital for expansion or balance sheet strengthening.
Granules India Q3 FY26: Revenue Up 22% to ₹1,388 Cr, EBITDA Grows 34% with Margin Expansion
Granules India reported a strong Q3 FY26 with revenue growing 22% YoY to ₹1,388 crores, driven by robust performance in North America and Europe. EBITDA increased 34% to ₹308 crores, with margins expanding to 22.2% despite a ₹24.8 crore loss in the nascent Peptide CDMO segment. The company is making steady progress on regulatory remediation at its Gagillapur facility, following a constructive meeting with the US FDA in January 2026. Additionally, shareholders have approved a preferential issue to strengthen the balance sheet and fund future capacity expansions.
Key Highlights
Revenue grew 22% YoY to ₹1,388 crores, while EBITDA rose 34% to ₹308 crores.
Gross margins improved by 216 bps YoY to 63.9% due to a better product mix in finished dosages.
Gagillapur remediation is on track with no concerns raised by the FDA regarding the pace of corrective actions.
Net debt stood at ₹1,015 crores with a cash-to-cash cycle of 202 days.
Peptide CDMO business (Ascelis) is expected to see meaningful improvement in Q4 FY26 following project deliveries.
👀 What to Watch
Investors should monitor the final resolution of the Gagillapur warning letter and the commercial scale-up of the high-margin Peptide CDMO business. The company's focus on complex generics and integrated manufacturing continues to drive operational leverage.
